PMC10062417_01
Clinical history. DG, diagnosis; IM, imatinib; Hem. relapse, hematological relapse (see text).
fonc-13-1117781-g001.jpg
PMC10062417_01_fonc-13-1117781-g001.jpg
f1
Sokal score. She was initially treated with Imatinib, but this drug was rapidly stopped because of intolerance, and she was switched to Dasatinib ( Figure 1 ). BCR::ABLIS levels rose to 25% in October 2017 and to 38% in September 2019 ( Figure 1 ). The first three were performed during periods of low BCR::ABL expression, whereas the last four were performed in samples with high BCR::ABL expression ( Figure 1 ).